- Home
- DBRG vs DYN Comparison
DBRG vs DYN Comparison
Compare DBRG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- DYN
- Stock Information
- Founded
- DBRG 1991
- DYN 1984
- Country
- DBRG United States
- DYN United States
- Employees
- DBRG N/A
- DYN N/A
- Industry
- DBRG Real Estate Investment Trusts
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DBRG Real Estate
- DYN Health Care
- Exchange
- DBRG Nasdaq
- DYN Nasdaq
- Market Cap
- DBRG 2.1B
- DYN 1.9B
- IPO Year
- DBRG 2009
- DYN 2020
- Fundamental
- Price
- DBRG $9.59
- DYN $18.84
- Analyst Decision
- DBRG Strong Buy
- DYN Strong Buy
- Analyst Count
- DBRG 8
- DYN 15
- Target Price
- DBRG $16.69
- DYN $36.53
- AVG Volume (30 Days)
- DBRG 3.7M
- DYN 3.1M
- Earning Date
- DBRG 10-30-2025
- DYN 11-05-2025
- Dividend Yield
- DBRG 0.42%
- DYN N/A
- EPS Growth
- DBRG N/A
- DYN N/A
- EPS
- DBRG 0.06
- DYN N/A
- Revenue
- DBRG $100,346,000.00
- DYN N/A
- Revenue This Year
- DBRG N/A
- DYN N/A
- Revenue Next Year
- DBRG $106.28
- DYN N/A
- P/E Ratio
- DBRG $89.11
- DYN N/A
- Revenue Growth
- DBRG N/A
- DYN N/A
- 52 Week Low
- DBRG $6.41
- DYN $6.36
- 52 Week High
- DBRG $14.00
- DYN $33.40
- Technical
- Relative Strength Index (RSI)
- DBRG 31.67
- DYN 51.17
- Support Level
- DBRG $10.39
- DYN $18.20
- Resistance Level
- DBRG $11.00
- DYN $20.07
- Average True Range (ATR)
- DBRG 0.62
- DYN 1.58
- MACD
- DBRG -0.28
- DYN -0.55
- Stochastic Oscillator
- DBRG 7.82
- DYN 22.76
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.